Drug Profile
Hyzetimibe - Zhejiang Hisun Pharmaceutical
Alternative Names: HS-25Latest Information Update: 30 Nov 2022
Price :
$50
*
At a glance
- Originator Zhejiang Hisun Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hypercholesterolaemia
Highest Development Phases
- Phase III Hypercholesterolaemia
- No development reported Hyperlipidaemia
Most Recent Events
- 30 Nov 2022 Hyzetimibe is still in phase III trials for Hypercholesterolaemia (Zhejiang Hisun Pharmaceutical pipeline, November 2022)
- 30 Nov 2022 Hyzetimibe is still in phase-III clinical trials for Hypercholesterolaemia (Combination therapy) in USA (PO) (Zhejiang Hisun Pharmaceutical pipeline, November 2022)
- 10 Oct 2018 Zhejiang Hisun Pharmaceutical completes a phase III trial in Hypercholesterolaemia (NCT03433196)